These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12639248)

  • 1. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.
    Kitabwalla M; Ferrantelli F; Wang T; Chalmers A; Katinger H; Stiegler G; Cavacini LA; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):125-31. PubMed ID: 12639248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
    Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM
    J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    Trkola A; Pomales AB; Yuan H; Korber B; Maddon PJ; Allaway GP; Katinger H; Barbas CF; Burton DR; Ho DD
    J Virol; 1995 Nov; 69(11):6609-17. PubMed ID: 7474069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    Mascola JR; Louder MK; VanCott TC; Sapan CV; Lambert JS; Muenz LR; Bunow B; Birx DL; Robb ML
    J Virol; 1997 Oct; 71(10):7198-206. PubMed ID: 9311792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
    Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
    J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.
    Stiegler G; Kunert R; Purtscher M; Wolbank S; Voglauer R; Steindl F; Katinger H
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1757-65. PubMed ID: 11788027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
    Gray ES; Meyers T; Gray G; Montefiori DC; Morris L
    PLoS Med; 2006 Jul; 3(7):e255. PubMed ID: 16834457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
    Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
    J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
    Li A; Katinger H; Posner MR; Cavacini L; Zolla-Pazner S; Gorny MK; Sodroski J; Chou TC; Baba TW; Ruprecht RM
    J Virol; 1998 Apr; 72(4):3235-40. PubMed ID: 9525650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
    Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.
    Gorny MK; Williams C; Volsky B; Revesz K; Wang XH; Burda S; Kimura T; Konings FA; Nádas A; Anyangwe CA; Nyambi P; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2006 Jul; 80(14):6865-72. PubMed ID: 16809292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
    Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
    AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.
    Chong H; Hong K; Zhang C; Nie J; Song A; Kong W; Wang Y
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):535-43. PubMed ID: 18209676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.
    Zhang G; Lu H; Lu Y; Jiang S; Chen YH
    Immunobiology; 2005; 210(9):639-45. PubMed ID: 16323702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.